
Biopharmaceutical company SpyGlass Pharma's SGP.O shares surge as much as 50% in Nasdaq debut
Stock opened at $24 apiece vs $16 IPO price
SGP sold ~9.4 million shares within marketed range of $15 and $17 to raise $150 million
Founded in 2019 by Malik Kahook and Glenn Sussman, SGP is building a portfolio of drug delivery systems to provide long-acting therapy for chronic eye diseases
SGP's lead program, the BIM-IOL system, integrates glaucoma treatment into standard cataract surgery
Jefferies, Leerink Partners, Citigroup and Stifel were joint book-running managers for offering